Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALR Technologies SGALRTF +9.39% 3-Year EBITDA Growth Rate is 20.60% as of Dec. 2025, which is 75% above its 10-year median of 11.80. The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, ALR Technologies SG ranks better than 66.47% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -0.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ALR Technologies SG was 35.90% per year. The lowest was -55.40% per year. And the median was 11.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ALR Technologies SG 3-Year EBITDA Growth Rate Related Terms
ALRTF vs VNRX, ADGM, NXL: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, ALR Technologies SG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALR Technologies SG 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ALR Technologies SG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ALR Technologies SG's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.60% mean?
ALR Technologies SG (ALRTF) has a 3-Year EBITDA Growth Rate of 20.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ALR Technologies SG and its competitors. This is 75% above median its historical median of 11.80. According to the industry distribution chart, ALR Technologies SG ranks #232 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 33.5%.
Is ALR Technologies SG's 3-Year EBITDA Growth Rate too high?
ALR Technologies SG's current 3-Year EBITDA Growth Rate of 20.60% is 75% above median its 10-year median of 11.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. ALR Technologies SG's value of 20.60% is 151.2% above this industry median. Based on the distribution chart, ALR Technologies SG ranks #232 out of 692 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does ALR Technologies SG's 3-Year EBITDA Growth Rate compare to VNRX and ADGM?
According to the Medical Devices & Instruments industry distribution chart, ALR Technologies SG ranks #232 out of 692 companies for 3-Year EBITDA Growth Rate. This puts ALR Technologies SG in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. ALR Technologies SG's value of 20.60% is 151.2% above this benchmark. While the company's 10-year median is 11.80 vs. the industry median of 8.20, ALR Technologies SG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ALR Technologies SG's current 3-Year EBITDA Growth Rate of 20.60% is 151.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ALR Technologies SG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALR Technologies SG's current 3-Year EBITDA Growth Rate is 20.60%, which is 75% above median its own 10-year median of 11.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALR Technologies SG stock overvalued right now?
ALR Technologies SG (ALRTF) has a current 3-Year EBITDA Growth Rate of 20.60%. The current 3-Year EBITDA Growth Rate is 20.60%, which is 75% above median its 10-year median of 11.80 and 151.2% above the Medical Devices & Instruments industry median of 8.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ALR Technologies SG (ALRTF), the current 3-Year EBITDA Growth Rate is 20.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALR Technologies SG Ltd is a medical device company that focuses on commercializing its Health-e-Connect System. The company is a data management company that developed a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA-compliant Diabetes Solution product that can collect data from BGM and CGM; a patent-pending Predictive A1C algorithm to track treatment success between lab reports; and an FDA-cleared Insulin Dosing Adjustment program. Geographically, it operates in the United States and Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALRTF has been successfully added to your 
